Tuesday, 17th November COSA 2015 ASM

Speakers: Assoc Prof Gerald Fogerty, Michael Dally, John Kenny

Content: Windsor pointed out that little progress has been made with whole brain radiotherapy (WBRT) over the last 50 years with the median survival remaining 4 months. Some progress has been made with a small number (1-3) of intracerebral metastases with the advent of Stereotactic Radiosurgery. Recent studies have confirmed the adverse neurocognitive effects of WBRT while a novel Japanese study has shown no detriment in treating a larger number of metastases (5-10) in terms of survival. What is unknown is the effect of stereotactic radiosurgery on more than 3 metastases in terms of neurocognitive function and local control. Treating large numbers of metastases with SRS with Linac-based technology has remained difficult because of the integral dose associated with multiple isocentres. BrainlabAG Automatic Brain Metastases Planning “Elements” software has been commissioned at Epworth Healthcare and is being used in a Phase II study of Stereotactic Hypo-fractionated Radiosurgery including Neurological and Cognitive assessment. With “SHRINC” we hypothesize that there will be no decline in neurocognitive function with SRS to multiple brain metastases. We hope to question current practice and share our early experience in commissioning and using BrainlabAG Elements software, to simultaneously treat up to ten metastases.

Welcome  by COSA President

Welcome to Country by local Indigenous group

Official opening by Prof Kate Warner AM (Governor of Tasmania)

• Classifying rare cancers. What is a rare cancer? - Angelo Dei Tos
• Diagnosis and management of rare tumors – A structured approach - Derek Raghavan
• Rare diseases learning from rare cancers - Hugh J.S Dawkins
• Rare cancers and existential uncertainty - David Kissane

• Approach to diagnosing rare cancers - Angelo Dei Tos
• Merkel Cell Carcinoma of the skin- Research into a rare malignancy. - Michael G Poulsen
• Furnishing the Genetic Firepower in Phaeochromocytoma - Nicholas Pachter
• Super-Duper Rare Thyroid Cancers - John Watkinson
• Small cell cancer of the ovary - Heather Cunliffe

• How can we better measure and address socio-demographic disadvantage in cancer outcomes? - Hanna Tervonen
• Closing the Gap in cancer outcomes for Indigenous people - Rajah Supramaniam
• Under-served populations – strategy, structure and function of programmatic approaches - Derek Raghavan
• Socio-economic perspectives that influence cancer patient outcomes in Australia, including health literacy - Carrie Lethborg

• Environmental aspects of cancer clusters - Bernard W Stewart
• Investigating cancer clusters - Leeka Kheifets
• Familial Cancer Clusters - Paul James
• The dos and don'ts for organisations responding to clusters - Tim Driscoll

• Evaluation of a web based cognitive rehabilitation programme (CRP) in cancer survivors reporting cognitive symptoms following chemotherapy - Victoria J Bray
• The Lymphocyte-to-Monocyte ratio is a superior predictor of OS in comparison to established biomarkers in CRC patients undergoing curative resection. - Joseph Chan
• SIRFLOX: Randomised phase III trial comparing first-line mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 ± bev + selective internal radiation therapy (SIRT) in patients with metastatic colorectal cancer (mCRC) - analysis by presence or absence of extra-hepatic metastases, bev treatment and site of first progression - Peter Gibbs
• Density of Foxp3⁺ regulatory T cells correlates with radioresponsiveness in locally advanced rectal cancer - Chris Hemmings
• Exploring the feasibility and utility of exome-scale sequencing of tumours in a clinical setting - Belinda Lee
• The impact of physical activity on fatigue and quality of life in lung cancer patients: a randomised controlled trial. - Haryana Dhillon

• Non-small cell lung cancer cells promote multiple changes in normal bronchial epithelial cells - Anne-Marie Baird
• ‘National Aboriginal and Torres Strait Islander Cancer Framework; directions and priorities’ - Jennifer Chynoweth
• Updated recommendations for the use of hypofractionated radiotherapy for early (operable) breast cancer - Sarah Norris
• Engaging multidisciplinary teams in translational research and quality improvement - Tim Shaw
• Epithelial-Mesenchymal Plasticity Status in Circulating Tumour Cells of Breast Cancer Xenograft Models - Erik W Thompson
• A novel literature-based approach to identify genetic and molecular predictors of survival in glioblastoma multiforme: Analysis of 14,678 patients using systematic review and meta-analytical tools - Matthew Thuy

• Clinical management of sarcoma - Brian O'Sullivan
• Pancreatic neuroendocrine tumours in MEN 1 – basic science & clinical management - John Burgess
• Rare molecular mutations in metastatic melanoma - Poulam M Patel

• Elucidating inflammatory meditated mechanisms of intrinsic and acquired chemo-resistance in non-small cell lung cancer  - Anne-Marie Baird
• Histopathology and genomics of tumours: a translational issue in biomedical science - Leon P Bignold
• Hematopoietic stem cell transplantation, survivorship and quality of life : Is it a small world after all?  - Lisa Brice
• Association of ABCA1 cholesterol transporter with poor outcome and aggressive phenotype in serous ovarian cancer. - Ellen L Hedditch
• Determining the impact of additional public radiotherapy services on the public radiotherapy utilisation rate in Queensland - Peter McGuire
• Comparative 2D and 3D Culture Studies as a Means to Identify Mechanisms of Chemo-Resistance - Anne-Marie Baird
• Implementing a shared care model to prevent liver cancer and improve chronic hepatitis B outcomes in a high disease prevalence area.  - Kristen Stone
• TGFB-RELATED SIGNATURE OF EMT IDENTIFIES BASAL SUBTYPE OF BREAST CANCER - E W Thompson
• Predictive value of de novo and induced epithelial-mesenchymal transition in locally advanced breast cancer treated with neoadjuvant chemotherapy - Erik W Thompson
• Final Report of a Phase I Trial of Lipovaxin-MM, a Novel Dendritic Cell-Targeted Liposomal Vaccine for Malignant Melanoma. - M N Abbas
• Evaluation of response from axitinib as per Choi criteria in previously treated patients with metastatic renal cell carcinoma (mRCC) - Louise Nott
• Utility of commonly available clinical parameters for predicting concurrent chemoradiotherapy toxicity following treatment of inoperable stage III non-small cell lung cancer. - sayed ali
• Pembrolizumab for Metastatic Melanoma – One Year Results of Named Patient Access Program - Vladimir Andelkovic
• Outcome of patients with stage III non-small cell lung cancer treated with neo adjuvant chemotherapy and radiotherapy in a tertiary care center - Wei-Sen Lam
• A review of skin outcomes for 100 patients treated with radiotherapy for skin cancer (SCC, BCC) and breast cancer at a local metropolitan hospital from 2011 – 2014 using a quantitative, non-experimental retrospective methodology. - Carol Baines
• PARAGON- An ANZGOG Phase 2 study of anastrazole in asymptomatic women with estrogen (ER)/ progesterone (PR) positive ovarian cancer with a CA125 progression after first line treatment. - Philip Beale
• Nivolumab (Nivo) monotherapy or in combination with ipilimumab (Ipi) for treatment of recurrent small cell lung cancer (SCLC) - Emiliano Calvo
• Patient Medication Access Programs for the Treatment of Cancer. Patterns of Use and Patient Outcomes at a Tertiary Metropolitan Hospital - Christine V Carrington
• Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma (mRCC): association of biomarkers with clinical outcomes - Toni K Choueri
• Treatment Outcome for Elderly Patients with Non small cell  Lung Cancer (NSCLC) - Sophie Conroy
• Patient Adherence to Aromatase Inhibitor Treatment in Early Stage Breast Cancer – local experience from Western Sydney hospitals - Sonia Cuan
• Smoking and the influence of behavioural factors in the outcomes of patients with colon cancer - Rachel Delahunty
• Impact of Chemotherapy-induced Alopecia on Cancer Patients in Regional Victoria - Cynthia Dixon
• The experience of survival following Blood and Marrow Transplant in NSW, Australia. - Gemma Dyer
• Rare data for a  common cancer: Survival Outcomes for Metastatic Breast Cancer (MBC) at Eastern Health, Victoria, Australia - Danielle A Ferraro
• An update on the ANZMTG 01.07 WBRTMel trial – The role of Adjuvant whole brain radiotherapy for patients with melanoma brain metastases - Gerald Fogarty
• Expanded cohort results from CheckMate 016: a Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC) - Hans J Hammers
• Longer-term follow-up of a phase 2 study (CheckMate 063) of nivolumab in patients with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC) - Leora Horn
• Safety and efficacy of nivolumab in an ongoing trial of a PD-L1^+/- patient population with metastatic non-small cell lung cancer - Maen Hussein
• A PILOT STUDY TO ASSESS VALIDITY OF THE DASS-21SUBSCALES IN AN OUTPATIENT ONCOLOGY POPULATION - Claire E Johnson
• Baseline predictors of early treatment failure in patients with Platinum Resistant/ Refractory (PRR) and Potentially Platinum Sensitive (PPS) recurrent ovarian cancer (ROC) receiving ≥3 lines of chemotherapy- The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS) - Peey-Sei Kok
• Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067) - James Larkin
• Safety and efficacy of microwave ablation in colorectal pulmonary metastases: 1-year follow-up - Chris R Luis
• Subsequent line of therapy in metastatic NSCLC (mNSCLC): an indicator of success or failure? - Eric S Nadler
• Patterns of driver mutations in routine multigene diagnostic profiling in 1865 patients - Sandra O'Toole
• Assessing the multidisciplinary lung cancer service: is best practice care evident? - Barbara J Page
• Treatment Outcome for The Elderly Patients with Small Cell Lung Cancer - Shivanshan Pathmanathan
• Identifying opioid medication error types, incidence and patient impact in adult oncology and palliative care settings: a systematic review. - Jane L Phillips
• Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC) - Elizabeth R Plimack
• Why adjuvant chemotherapy for stage III colon cancer was not given: reasons for non-recommendation by clinicians or patient refusal. - Khageshwor Pokharel
• Phase 3, randomized trial (CheckMate 017) of nivolumab (Nivo) vs docetaxel in advanced squamous (SQ) cell non-small cell lung cancer (NSCLC) - Karen Reckamp
• Size matters: peripherally inserted central catheter (PICC) diameter and risk of upper-extremity thrombus in cancer patients – a pilot study. - Rebecca Sharp
• Sensorineural Hearing Loss: Who is most at risk? - Phoebe Shorter
• Exercising during neo-adjuvant chemoradiation therapy for rectal cancer patients: a feasibility study. - Favil Singh
• Supervised exercise during cancer treatment maintains or improves body composition and function. - Favil Singh
• ‘Rethinking REAL-2: Real-life outcomes from an Australian retrospective audit of patients with metastatic oesophago-gastric adenocarcinoma (mOGC)’ - Claudia E.A Stretch
• Implementation of Postoperative Nutritional Support for Gastric Cancer Patients in China - Bin Zhu
• Quality of life and cytokine gene variation in breast, prostate, lung and brain cancer patients and their family caregivers - Kimberly Alexander
• Sun Protection Practices of Undergraduate University Students  - sayed ali
• To assess the timeliness of access to treatment for patients with thoracic malignancies referred to MDM in the ACT Region - Madhawa De SIlva
• Changing patterns of Pancreaticoduodenectomy surgery in Queensland - Nathan Dunn
• Are rare cancers killing our young people? - Nathan Dunn
• Suitable for chemotherapy? An analysis of an Australian geriatric oncology population - Harriet Herbison
• Lenalidomide use in relapsed or refractory multiple myeloma patients at five large Queensland public hospitals. - Daniel McKavanagh
• Temporal trends in the risk of developing multiple primary cancers: A systematic review - Yuanzi Ye
• Evidence into practice: Dietetic and Speech Pathology Service for Gold Coast University Hospital Head and Neck cancer patients undergoing radiation therapy - JESSICA ABBOTT
• Home-based Cancer Care: a Regional Perspective - Natalie Ashley
• ISCaHN Treatment Dashboard: Providing clinician decision support with data generated at the point of care. - Graeme Bell
• Transversing the Silos - Maria M Boland
• Diminishing disparities with an online blended-learning approach - Eliza Bott
• Tips and tricks for the successful implementation of a learning management system - Eliza Bott
• MANAGEMENT OF COMPLEX DISCHARGE PLANNING IN THE SETTING OF CANCER NURSING - Carla Thamm
• An Innovative Interdisciplinary approach to Cancer Care Services “Removing the Band-Aid Effect”.  Model of Care of Cancer Allied Health - Dawn Hutley and jacqueline Hampton
• Lung Cancer Quality Improvement Study - Gold Coast University Hospital - Samuel P Jones
• Nutritional status, weight loss and associated characteristics of patients with oesophageal and gastro-oesophageal (GOJ) cancer: a descriptive study - Ka Hi (May) Mak
• Is routine malnutrition screening needed at Liverpool Cancer Therapy Centre? - Ka Hi (May) Mak
• “Self-reported satisfaction and outcomes based on referral source into Cancer Council WA Counselling Program” - Lesley Millar
• A Quality Analysis on the Functionality of Multidisciplinary Teams - Kylie Museth
• Implementing best practice approaches for the management of lung cancer: a national approach - Caroline Nehill
• Shared follow-up care for early breast cancer - Caroline Nehill
• Multidisciplinary approach to weight management in oncology patients- “Why weight?” - Rebecca Nunes
• Convenient Chemotherapy– A New Paradigm for Pharmacy - Niamh O'Neill
• Pre-screening for capacity to consent as a potential family bone marrow donor - Maria Presta
• Development and implementation of a multidisciplinary support program for carers of patients undergoing allogeneic haematopoietic stem cell transplantation - Maria Presta
• You Told Us, We Listened, We Acted: A Multidisciplinary Project Team Creating A More Therapeutic Cancer Care Environment By Partnering With Consumers  - Sue Schoonbeek
• Are you ready to accept accountability? Improving patient safety and satisfaction in an acute oncology/haematology unit using a uniform clinical handover tool - Carla Thamm
• From Sleepy Hollow to Survivorship Superstar: An example of Transformational Leadership in community cancer care - Merran Z Williams
• Integrating Cancer Self Management Strategies - Ilana Solo
• Parking at Victorian cancer treatment centers – issues and impacts - Anna Boltong
• Implementation and evaluation of Lung Cancer Patient Seminar 2014 - Puey Ling Chia
• Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice - Joel Cohen (Presenter on behalf of investigators)
• Efficacy and reach of psychosocial interventions for improving cognitive functions in cancer survivors - Heather J Green
• Evaluating patient information: Understanding Radiotherapy - Elizabeth Humphries
• Unmet Needs of Asian and Caucasian Women with Breast Cancer: Findings from the Literature - Janelle Levesque
• Oncology patients’ attitudes toward, and experiences with, somatic mutation tumour testing - Roger Liang
• Changing our ways: Developing an advanced practice role for dietitians - Belinda Steer
• A REVIEW OF THE BLOOD TRANSFUSIONS IN CANCER PATIENTSTRASNFUSIONS - Padmini Thanayankezhil
• The experiences and preferences of shared decision making and their associated factors among cancer patients undergoing radiation therapy     - Megumi Uchida
• Self-guided psychological interventions for people with cancer: A systematic review - Anna Ugalde
• Why won’t patients with advanced cancer engage in ACP: Experience from an Australian ACP RCT - Martin Tattersall
• A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours: The P3BEP Trial (ANZUP 1302) - Howard Chan
• Randomised phase 3 trial of the addition of Mitomycin  to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer(ANZUP 1301) - Howard Chan
• Precision medicine for advanced pancreas cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) trial - Lorraine Chantrill
• Randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer: the ANZUP ENZAMET Trial (ANZUP 1304) - Ian Davis
• Randomised phase 3 double-blind placebo-controlled trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasound-guided prostate biopsy (Pain-Free TRUS B): ANZUP 1501 - Ian Davis
• Rekindle Update: Rekindle is Demonstrating Broad Reach Across Australia in Providing Psychosexual Support to BOTH Cancer Survivors and Their Partners  - Haryana Dhillon
• OPAL: On-line and Phone Assistance for Lung cancer patients: A randomised controlled trial of on-line versus telephone-based information and support via Cancer Council services - Christine Paul
• Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate  cancer: ENZARAD (ANZUP 1303) - Scott G Williams

• Timing and patterns of referral to palliative care for patients with metastatic non-small cell lung cancer (NSCLC) in South Western Sydney Local Health District (SWSLHD). - Peey-Sei Kok
• A complex cocktail: polypharmacy, potentially inappropriate medications and palliative cancer patients.     - Emily D'Arcy
• Stereotactic Radiotherapy for Intracranial Haemangiopericytoma - 'Dose and Outcome' - Rohan Dr Nair
• Interim results of a pilot chemoradioembolisation study in uveal melanoma liver metastasis - Sagun Parakh
• Intraductal Carcinoma of the Prostate (IDC-P) in Men with High Risk Prostate Cancer (PCa) Survives Androgen Deprivation Therapy.  - Carmel Pezaro

• Building the bridge from discovery-to-delivery: A Community of Practice in Cancer Implementation Science - Candice Kielly-Carroll
• Cancer Consumer Involvement in Research in AustraliaCelebrating ten years (2005 – 2015) of Cancer Voices’ CIR Program - Sally Crossing AM
• Development and acceptability of a radiation therapy talking book for people with low health literacy - Haryana M Dhillon
• Oral Antineoplastic Drugs – the role Community Pharmacists play in facilitating safe and effective use - Aisling Kelly
• The development of an Indigenous cancer network - lessons learned - Bronwyn Morris

• Ongoing high quality randomised trials are helping define the role of Radiotherapy in melanoma - Gerald Fogarty
• Ocular melanoma - Poulam M Patel
• Surgery and Stage IV Melanoma - David Speakman
• To hope or not to hope; that is the question. - Christine Clifford

• Pathology of Sarcomas - Angelo Dei Tos
• Managing sarcoma from a medical oncologist perspective - David M Thomas
• Managing sarcoma from a radiation oncologist perspective - Brian O'Sullivan
• Current Trends in Sarcoma Surgery - David Wood
• Sarcoma - Luke Ryan

• An update on sigNETure – the NETs registry - Yu Jo Chau
• CONTROL NETS: Capecitabine ON Temozolomide Radionuclide therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study - Katrin M Sjoquist
•  Visualising Therapy: Evolving role of nuclear medicine in Management of Metastatic Neuroendocrine Tumours - Michael S Hofman
• Cardiac Valve Surgery in patients with Carcinoid Heart Disease - Marco Larobina
• The Patient and Carer Perspective of NETs – What have we learnt and direction for the future - Simone Leyden

• Does stress increase risk of cancer? A 15 year prospective study of women at high risk of breast cancer - Phyllis N Butow
• Effectiveness of exercise for people diagnosed with rare and less common cancers - Prue Cormie
• The Melanoma Care Study a psycho-educational intervention for people with melanoma at high risk of developing a new primary: A pilot randomised controlled trial - Mbathio Dieng
• Translating Research Into Practice: The Healthy Living after Cancer Partnership Project - Elizabeth Eakin
• A systematic review of psychotherapeutic interventions for women with metastatic breast cancer: Implications and recommendations for developing an online self-help program. - Lisa Beatty
• Scalp Cooling: A qualitative study to assess the perceptions and experiences of Australian health professionals working in breast cancer - Joanne Shaw

• Rare cancers in Queensland: quantifying the impact - Nathan Dunn
• Patient-reported quality of life and depression in women with ovarian cancer - why ignoring the patterns of missing data can bias research conclusions - Rebecca Mercieca-Bebber
• Fertility Implications for Women with a BRCA1 or BRCA2 Germline Mutation - Kelly-Anne Phillips
• High dose azathioprine increases the risk of malignancy in solid organ transplant recipients - Claire Vajdic
• Estimating rare cancer net survival in New South Wales: Comparison of Ederer II and Pohar-Perme estimators - Hui You

Off site venue – visit the MSD stand for more information

Content: The idea of immunotherapy for cancer is not a new one. In the 1890s, a New York surgeon named William Coley noted that a patient's cancer seemed to vanish after he came down with a bacterial infection. But more than 100 years passed with little advancement and much frustration. More recently, the field has taken significant steps forward, as clinical developments have translated into improved patient outcomes. Although there are many unanswered questions, our understanding and application of immunotherapy has transformed the landscape for many cancers.

Specifically designed for medical oncologists, oncology nurses, pharmacists and the entire multidisciplinary team involved in treating cancer patients with immunotherapy, this session will reflect on the shift away from more traditional chemotherapies to immunotherapies for cancers such as melanoma. We will review our understanding of key clinical aspects including the underlying principles of tumour immunology, patient initiation and management on immunotherapy, and practical considerations including reconstitution and managing the infusion.

Speakers: Michael Michael, Stephen Clarke, David Chan, Yu Jo Chua

Content:  A scientific symposium to present pivotal data in the treatment of NETS. Considering the clinical implications for patients, and asking, is it a time for change? 

The Concept – Michael Michael 

The Clinical Data – David Chan 

Case Studies with Audience Participation – Stephen Clarke 

Guidelines and Recommendations – Yu Jo Chua 

Future Prospects – Yu Jo Chua

Questions session – Facilitated by Michael Michael

Close – Michael Michael